Silexion Therapeutics Corp. (SLXN)
0.2146
-0.02
(-8.64%)
USD |
NASDAQ |
Oct 09, 16:00
0.204
-0.01
(-4.94%)
After-Hours: 20:00
Silexion Therapeutics Enterprise Value : -0.5948M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | -0.5948M |
| October 08, 2026 | -0.5709M |
| October 07, 2026 | -0.5488M |
| October 06, 2026 | -0.5379M |
| October 05, 2026 | -0.5342M |
| October 02, 2026 | -0.5414M |
| October 01, 2026 | -0.5188M |
| September 30, 2026 | -0.5208M |
| September 29, 2026 | -0.4724M |
| September 28, 2026 | -0.5549M |
| September 25, 2026 | -0.5409M |
| September 24, 2026 | -0.5448M |
| September 23, 2026 | -0.476M |
| September 22, 2026 | -0.3852M |
| September 21, 2026 | -0.2061M |
| September 18, 2026 | -0.3342M |
| September 17, 2026 | -0.3997M |
| September 16, 2026 | -0.4469M |
| September 15, 2026 | -0.4469M |
| September 14, 2026 | -0.3933M |
| September 11, 2026 | -0.4265M |
| September 10, 2026 | -0.3495M |
| September 09, 2026 | -0.4357M |
| September 08, 2026 | -0.4411M |
| September 04, 2026 | -0.4329M |
| Date | Value |
|---|---|
| September 03, 2026 | -0.4332M |
| September 02, 2026 | -0.4337M |
| September 01, 2026 | -0.4114M |
| August 31, 2026 | -0.4118M |
| August 28, 2026 | -0.42M |
| August 27, 2026 | -0.423M |
| August 26, 2026 | -0.4293M |
| August 25, 2026 | -0.4174M |
| August 24, 2026 | -0.4143M |
| August 21, 2026 | -0.383M |
| August 20, 2026 | -0.3773M |
| August 19, 2026 | -0.3605M |
| August 18, 2026 | -0.3546M |
| August 17, 2026 | -0.3501M |
| August 14, 2026 | -0.3522M |
| August 13, 2026 | -0.3053M |
| August 12, 2026 | -0.3123M |
| August 11, 2026 | 0.3731M |
| August 10, 2026 | 0.9217M |
| August 07, 2026 | 1.358M |
| August 06, 2026 | 1.264M |
| August 05, 2026 | 1.276M |
| August 04, 2026 | 1.394M |
| August 03, 2026 | 1.453M |
| July 31, 2026 | 1.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLineRx Ltd. | 7.392M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 407.84M |
| Can-Fite BioPharma Ltd. | -4.811M |
| Eocene Ltd. | -7.716M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.551M |
| Total Expenses (Quarterly) | 3.551M |
| EPS Diluted (Quarterly) | -5.166 |
| Earnings Yield | -26.35K% |
| Normalized Earnings Yield | -26480.99 |